Jared P Rutter

US Patent:

7132278, Nov 7, 2006

Filed:

Nov 19, 2001

Appl. No.:

10/059962

Inventors:

Steven L. McKnight - Dallas TX, US
Kevin Gardner - Dallas TX, US
Shannon Harper - Dallas TX, US
Jared Rutter - Dallas TX, US
Carolyn Michnoff - Dallas TX, US
Carlos Amezcua - Dallas TX, US

Assignee:

Board of Regents, The University of Texas System - Austin TX

International Classification:

C07H 21/04
C12N 5/00
C12N 1/16
C12N 15/00

US Classification:

435325, 43525411, 435194, 4353201, 536 235, 536 232, 536 231

Abstract:

The invention provides methods and compositions relating to a novel kinase designated PAS Kinase (PASK). The compositions include isolated polypeptides comprising a native PASK protein or a PASK N-terminal domain and polypeptides consisting of a PASK PAS-A or PAS-B domain, as well as isolated polynucleotides encoding such polypeptides, and expression vectors and cells comprising such polynucleotides. The methods include binding assays comprising the steps of incubating a mixture comprising a subject polypeptide with a ligand under conditions wherein the polypeptide binds the ligand; and detecting binding of the polypeptide to the ligand.

US Patent:

20050074846, Apr 7, 2005

Filed:

Oct 1, 2003

Appl. No.:

10/677734

Inventors:

Kevin Gardner - Dallas TX, US
Carlos Amezcua - Dallas TX, US
Paulus Erbel - Dallas TX, US
Paul Card - Dallas TX, US
Shannon Harper - Dallas TX, US
Jared Rutter - Salt Lake City UT, US
Richard Bruick - Dallas TX, US
Steven McKnight - Dallas TX, US

International Classification:

C07H021/04
C12N009/12

US Classification:

435069100, 435320100, 435194000, 435325000, 536023200

Abstract:

Specific binding of a foreign core ligand to a PAS domain, wherein the PAS domain is predetermined, prefolded in its native state, and comprises a hydrophobic core that has no NMR-apparent a priori formed ligand cavity, is determined by (a) detecting a first NMR spectrum of the PAS domain in the presence of a foreign ligand; and (b) comparing the first NMR spectrum with a second NMR spectrum of the PAS domain in the absence of the ligand to infer the presence the ligand specifically bound within the hydrophobic core of the PAS domain. A functional surface binding specificity of a PAS domain, wherein the PAS domain is predetermined, prefolded in its native state, and comprises a hydrophobic core that has no NMR-apparent a priori formed ligand cavity, is changed by (a) introducing into the hydrophobic core of the PAS domain a foreign ligand of the PAS domain; and (b) detecting a change in the functional surface binding specificity of the PAS domain.

US Patent:

20060051829, Mar 9, 2006

Filed:

Oct 11, 2005

Appl. No.:

11/245742

Inventors:

Kevin Gardner - Dallas TX, US
Carlos Amezcua - Dallas TX, US
Paulus Erbel - Dallas TX, US
Paul Card - Dallas TX, US
Shannon Harper - Dallas TX, US
Jared Rutter - Salt Lake City UT, US
Richard Bruick - Dallas TX, US
Steven McKnight - Dallas TX, US

International Classification:

C12Q 1/48
C12N 9/12

US Classification:

435015000, 435194000

Abstract:

A functional surface binding specificity of a PAS domain, wherein the PAS domain is predetermined, prefolded in its native state, and comprises a hydrophobic core that has no NMR-apparent a priori formed ligand cavity, is changed by (a) introducing into the hydrophobic core of the PAS domain a foreign ligand of the PAS domain; and (b) detecting a change in the functional surface binding specificity of the PAS domain.

US Patent:

20100256220, Oct 7, 2010

Filed:

Jun 7, 2007

Appl. No.:

12/303900

Inventors:

Jared Rutter - Salt Lake City UT, US
Wojtek Swiatek - Salt Lake City UT, US

Assignee:

University Of Utah Research Foundation - Salt Lake City UT

International Classification:

A61K 31/7088
A61P 3/10
A61P 3/04
C40B 30/00
C12Q 1/48

US Classification:

514 44 R, 506 7, 435 15

Abstract:

Disclosed are compositions and methods related to PAS Kinase (PASK) and various diseases and disorders associated therewith. Included are methods for treating insulin resistance, cancer, and diabetes comprising administering a composition that inhibits PAS Kinase. Further included are methods, including high throughput screening methods, for identifying test compounds that modulate PAS Kinase.

US Patent:

20110165560, Jul 7, 2011

Filed:

Jul 6, 2010

Appl. No.:

12/831141

Inventors:

JARED RUTTER - SALT LAKE CITY UT, US
HUAIXIANG HAO - MALDEN MA, US
JOSHUA SCHIFFMAN - SALT LAKE CITY UT, US

International Classification:

C12Q 1/68
G01N 33/48
C12N 15/63

US Classification:

435 61, 436 94, 4353201

Abstract:

The present invention provides methods, compositions, and kits associated with succinate dehydrogenase-related disease conditions. In one aspect of the present invention, a method for screening a test subject to determine risk for developing a succinate dehydrogenase-related disease condition is provided. Such a method can include obtaining a biological sample from the test subject and identifying a mutation in gene hSDH5 from the biological sample of the test subject, wherein the mutation effectuates a decreased level of succinate dehydrogenase flavination in the test subject as compared to a level of succinate dehydrogenase flavination in a normal subject. In one aspect, the mutation is at hSDH5 Gly78 of gene hSDH5. In another aspect, the mutation is equivalent to an hSDH5 Gly78Arg substitution of gene hSDH5.

US Patent:

63196794, Nov 20, 2001

Filed:

Jan 26, 2001

Appl. No.:

9/770170

Inventors:

Steven L. McKnight - Dallas TX
Kevin Gardner - Dallas TX
Shannon Harper - Dallas TX
Jared Rutter - Dallas TX
Carolyn Michnoff - Dallas TX
Carlos Amezcua - Dallas TX

Assignee:

Board of Regents, The University of Texas System - Austin TX

International Classification:

C12Q 148

US Classification:

435 15

Abstract:

The invention provides methods and compositions relating to a novel kinase designated PAS Kinase (PASK). The compositions include isolated polypeptides comprising a native PASK protein or a PASK N-terminal domain and polypeptides consisting of a PASK PAS-A or PAS-B domain, as well as isolated polynucleotides encoding such polypeptides, and expression vectors and cells comprising such polynucleotides. The methods include binding assays comprising the steps of incubating a mixture comprising a subject polypeptide with a ligand under conditions wherein the polypeptide binds the ligand; and detecting binding of the polypeptide to the ligand.